E-viri
Recenzirano
Odprti dostop
-
Nery, Filipe; Chevret, Sylvie; Condat, Bertrand; de Raucourt, Emmanuelle; Boudaoud, Larbi; Rautou, Pierre‐Emmanuel; Plessier, Aurelie; Roulot, Dominique; Chaffaut, Cendrine; Bourcier, Valerie; Trinchet, Jean‐Claude; Valla, Dominique‐Charles
Hepatology (Baltimore, Md.), February 2015, 2015-Feb, 2015-02-00, 20150201, Letnik: 61, Številka: 2Journal Article
In cirrhosis, portal vein thrombosis (PVT) could be a cause or a consequence of the progression of liver disease. We analyzed data from a prospective trial of ultrasound screening for hepatocellular carcinoma in order to identify risk factors for and the impact of PVT in patients with cirrhosis. In all, 1,243 adults with cirrhosis without PVT were enrolled from 43 liver units in France and Belgium between June 2000 and March 2006. The mean follow‐up was 47 months. Doppler ultrasonography was used to check the portal vein. Progression of liver disease was defined by the development of: ascites, hepatic encephalopathy, variceal bleeding, prothrombin <45%, serum bilirubin >45 μmol/L, albumin <28 g/L, and/or creatinine >115 μmol/L. G20210A prothrombin and factor V gene mutations were assessed in sera stored at three large centers. The 5‐year cumulative incidence of PVT was 10.7%. PVT was mostly partial and varied over time. The development of PVT was independently associated with baseline esophageal varices (P = 0.01) and prothrombin time (P = 0.002), but not with disease progression before PVT, or prothrombotic mutations. Disease progression was independently associated with baseline age (hazard ratio HR 1.55; 95% confidence interval CI: 1.11‐2.17), body mass index (HR 1.40; 95% CI: 1.01‐1.95), prothrombin time (HR 0.79; 95% CI: 0.70‐0.90), serum albumin (HR 0.97; 95% CI: 0.94‐0.99), and esophageal varices (HR 1.70; 95% CI: 1.21‐2.38) but not with the prior development of PVT (HR 1.32; 95% CI: 0.68‐2.65). Conclusion: In patients with cirrhosis, the development of PVT is associated with the severity of liver disease at baseline, but does not follow a recent progression of liver disease. There is no evidence that the development of PVT is responsible for further progression of liver disease. (Hepatology 2015;61:660‐667)
![loading ... loading ...](themes/default/img/ajax-loading.gif)
Vnos na polico
Trajna povezava
- URL:
Faktor vpliva
Dostop do baze podatkov JCR je dovoljen samo uporabnikom iz Slovenije. Vaš trenutni IP-naslov ni na seznamu dovoljenih za dostop, zato je potrebna avtentikacija z ustreznim računom AAI.
Leto | Faktor vpliva | Izdaja | Kategorija | Razvrstitev | ||||
---|---|---|---|---|---|---|---|---|
JCR | SNIP | JCR | SNIP | JCR | SNIP | JCR | SNIP |
Baze podatkov, v katerih je revija indeksirana
Ime baze podatkov | Področje | Leto |
---|
Povezave do osebnih bibliografij avtorjev | Povezave do podatkov o raziskovalcih v sistemu SICRIS |
---|
Vir: Osebne bibliografije
in: SICRIS
To gradivo vam je dostopno v celotnem besedilu. Če kljub temu želite naročiti gradivo, kliknite gumb Nadaljuj.